<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="3" ids="16335">Adenosine</z:chebi> 5'-monophosphate-activated protein kinase (AMPK) is an important sensor of energy balance </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo>-induced AMPK activation is deleterious because both pharmacological inhibition and genetic deletion of AMPK are neuroprotective </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> is a known AMPK activator but reduces <z:hpo ids='HP_0001297'>stroke</z:hpo> incidence in clinical populations </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the effect of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and AMPK activation in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Male mice were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> after <z:hpo ids='HP_0011009'>acute</z:hpo> (3 days) or <z:hpo ids='HP_0011010'>chronic</z:hpo> (3 weeks) administration of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes, AMPK activation, <z:chebi fb="4" ids="24996">lactate</z:chebi> accumulation, and behavioral outcomes were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>The roles of neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase and AMPK were examined using mice with targeted deletion of AMPK or neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:chebi fb="0" ids="6801">metformin</z:chebi> exacerbated <z:hpo ids='HP_0001297'>stroke</z:hpo> damage, enhanced AMPK activation, and led to metabolic dysfunction </plain></SENT>
<SENT sid="8" pm="."><plain>This effect was lost in AMPK and neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase knockout mice </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="6801">metformin</z:chebi> given prestroke was neuroprotective, improved <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced <z:chebi fb="4" ids="24996">lactate</z:chebi> generation, and ameliorated <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced activation of AMPK </plain></SENT>
<SENT sid="10" pm="."><plain>Similarly, the neuroprotective effect of <z:hpo ids='HP_0011010'>chronic</z:hpo> prestroke <z:chebi fb="0" ids="6801">metformin</z:chebi> was lost in neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase knockout mice </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: AMPK is an important potential target for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment and prevention </plain></SENT>
<SENT sid="12" pm="."><plain>These studies show that the timing, duration, and amount of AMPK activation are key factors in determining the ultimate downstream effects of AMPK on the ischemic brain </plain></SENT>
</text></document>